Abstract

Simultaneous pancreas-kidney transplantation is an effective treatment for patients with type 1 diabetes mellitus and end-stage chronic kidney disease. Delayed pancreatic graft function is a common and multifactor condition with significant impact in short-term outcome of simultaneous pancreas-kidney transplantations. The aim of this study was to analyze the impact of pancreatic delayed pancreatic graft function on simultaneous pancreas-kidney transplantation. Donor and recipient's demographic data, percentage of panel reactivity, acute rejection incidence, and patient and grafts survivals were retrospectively analyzed in 180 SPKT performed between 2002 and 2007. The incidence of pancreatic delayed pancreatic graft function was 11%. Donors older than 45 years had significant risk of pancreatic delayed pancreatic graft function (OR 2.26; p < 0,05). Patients with pancreatic delayed pancreatic graft function had higher rates of acute renal rejection (47 versus 24%; p < 0.05), altered fasting plasma glucose (25 versus 5%; p < 0.05) and mean glycated hemoglobin (5.8 versus 5.4%; p < 0.05), than patients without pancreatic delayed pancreatic graft function at the end of the first year of follow up. There were no significant differences between patients with and without pancreatic delayed pancreatic graft function regarding patient survival (95 versus 88.7%; p = 0.38), pancreatic graft survival (90 versus 85.6%; p = 0.59) and renal graft survival (90 versus 87.2%; p = 0.70), respectively at the sample period of time. Pancreatic delayed pancreatic graft function had no significant impact in the short-term outcome of simultaneous pancreas-kidney transplantations. Although delayed pancreatic graft function had no impact on 1-year pancreas graft survival, it contributed to early pancreas graft dysfunction, as assessed by enhanced insulin and oral anti-diabetic drugs requirements.

Highlights

  • Simultaneous pancreas-kidney transplantation (SPKT) is a therapeutic modality accepted throughout the world for insulin-dependent patients with type 1 diabetes mellitus (DM) and end-stage chronic kidney disease, especially when they present inappropriate glycemic control, asymptomatic hypoglycemia, and lesions in target organs

  • The benefits of SPKT are not limited to glycemic control and treatment of end-stage uremia; it improves the disabling comorbidities related to long-lasting diabetes mellitus

  • This study aims at analyzing the results of the SPKT performed at Universidade Federal de São Paulo (Unifesp); the incidence and risk factors for the occurrence of Delayed pancreas graft function (DPGF); and the impact of DPGF on the short-term survival rates of patients and renal and pancreatic grafts

Read more

Summary

Introduction

Simultaneous pancreas-kidney transplantation (SPKT) is a therapeutic modality accepted throughout the world for insulin-dependent patients with type 1 diabetes mellitus (DM) and end-stage chronic kidney disease, especially when they present inappropriate glycemic control, asymptomatic hypoglycemia, and lesions in target organs. In the United States, survival rates of patients submitted to SPKT after 1 and 5 years of follow-up are 95% and 87%, respectively. The benefits of SPKT are not limited to glycemic control and treatment of end-stage uremia; it improves the disabling comorbidities related to long-lasting diabetes mellitus. Retinopathy related to DM estabilizes.[4] In addition, a significant reduction in the occurrence of cardiovascular episodes in the long term follow-up is often observed, as well as improvement in markers of atherosclerosis of coronary circulation and of performance of the left ventricle.[5,6,7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call